Bactiguard Holding AB (publ) (BACTI_B) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, Operator, and welcome to the presentation of Back to Guard's Q1 2025 report. Our CFO, Patrick Bach, and I will go through the presentation together, and as usual, we will have a Q&A session towards the end. I will begin by sharing some brief comments on the first quarter results, and Patrick will go through the financials in more detail later in the presentation. Firstly, we are very pleased to again report both continued profitability and revenue growth. We delivered an EBITDA of 9.4 million SEC and revenues of 62.7 million SEC, which is an increase of almost 7% compared to Q1 last year. Increased license revenues stem primarily from our strengthened collaboration with med tech company BD. a prime example of a mutually beneficial relationship that is driving growth for both parties. I will provide a bit more detailed update regarding the BD partnership shortly. Another highlight for Q1 comes from our wound management portfolio. Revenues increased by more than 50% driven by sales of our Hydrosyn Aqua line of products. We now have four quarters in a row with positive financial development demonstrating that we are consistently doing what we said we would do and delivering on our promise of profitability following the financial turnaround and strategic shift from 2024. As a major event during the quarter, in early March, we announced our updated strategic and financial targets to be achieved by year-end 2030, and I will take this opportunity to repeat them. First, more than 10 application areas in exclusivity or license partnerships, Second, revenues of at least 600 million SEC. And third EBITDA of at least 200 million SEC. In connection with the targets, we also revised our focus therapeutic areas for the licensed business. And I will also come back to this...